New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - bee venom 550ug - powder for injection - 550 mcg - active: bee venom 550ug excipient: mannitol sodium chloride albumin phenol sodium chloride sodium octanoate water for injection - albey honey bee venom, wasp venom and yellow jacket venom are indicated for the diagnosis and treatment of hypersensitivity to honey bee venom, wasp venom and yellow jacket venom respectively.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - honey bee venom, quantity: 550 microgram - injection, powder for - excipient ingredients: mannitol; sodium chloride - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alk-abello ltd - bee venom - powder and solvent for solution for injection - 120microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alk-abello ltd - bee venom - powder and solvent for solution for injection - 120nanogram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alk-abello ltd - bee venom - powder and solvent for solution for injection - 1.2microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alk-abello ltd - bee venom - powder and solvent for solution for injection - 12microgram

New Zealand - English - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - bee venom 120ug - powder for injection - 120 mcg - active: bee venom 120ug

United States - English - NLM (National Library of Medicine)

alk-abello a s - apis mellifera venom (unii: 76013o881m) (apis mellifera venom - unii:76013o881m) - apis mellifera venom 100 ug in 1 ml - the pharmalgen venom preparations are indicated for use in the diagnosis and treatment of hymenoptera sting allergy. the following general considerations should be applied in determining the proper use of these preparations: - approximately two-thirds of adult patients with a history of sting anaphylaxis and a positive venom skin test but who do not receive immunotherapy will experience a systemic reaction if stung by the implicated insect again. these patients should receive therapy4 . children whose reactions have been limited to the skin have an approximately 10% risk of future reactions if stung and not immunized. the nature and severity of these reactions is in general similar to the original reaction and therefore children with this kind of history may not need venom therapy5 . - the risk of anaphylaxis following a future sting is unknown in patients who have been stung without experiencing a systemic reaction but who are currently venom skin test positive. at this time, no recommendation can be made th

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - paper wasp venom, quantity: 550 microgram - injection, powder for - excipient ingredients: mannitol; sodium chloride - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - wasp venom protein 550ug (polistes) - powder for injection - 550 mcg - active: wasp venom protein 550ug (polistes) excipient: mannitol albumin phenol sodium chloride sodium octanoate water for injection - albey honey bee venom, wasp venom and yellow jacket venom are indicated for the diagnosis and treatment of hypersensitivity to honey bee venom, wasp venom and yellow jacket venom respectively.